A Precision T-Cell Therapy Stalls Treatment-Resistant Cancers in Clinical Trial
The study found selective Vδ6/Vδ10 T-cell activation and a manageable safety profile, with objective responses across several checkpoint-resistant tumor types.
7 Articles
7 Articles
Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial
Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J had gained access to the drug through its $3.05 billion deal to buy Halda Th...
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.
Marengo Therapeutics Announces Landmark Nature Medicine Publication Establishing First-in-Human Proof of Vβ-Directed T-Cell Biology and Antitumor Activity
/PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and...
Correio da Manhã
DnoticiasThe first phase of the START001 trial evaluated the experimental medicinal product 'invikafusp alfa'.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
